Toxic Effects
Toxic Effects - Related Videos
01:37
Evaluating the Neuroprotective Effects of a Test Compound Against Alpha-Synuclein Toxicity in Rat Embryonic Neurons
0 Views •
2025
Start with a primary midbrain culture from rat embryos, containing dopaminergic neurons that overexpress mutated alpha-synuclein.Replace the media in the treatment wells with fresh media containing the test compound, and that in the control wells with plain media. Then incubate.In the control, alpha-synuclein forms toxic aggregates in dopaminergic neurons, causing neurite retraction and leading to neuronal death.In the treatment, the test compound interacts with alpha-synuclein, prevents its...
05:27
Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products
0 Views •
Cited by 15 •
2016
This protocol describes a scalpel loading-fluorescent dye transfer technique that measures intercellular communication through gap junction channels. Gap junctional intercellular communication is a major cellular process by which tissue homeostasis is maintained and disruption of this cell signaling has adverse health effects.
08:58
Using Caenorhabditis elegans for Studying Trans- and Multi-Generational Effects of Toxicants
0 Views •
Cited by 9 •
2019
Trans- and multi-generational effects of persistent chemicals are essential in judging their long-term consequences in the environment and on the human health. We provide novel detailed methods for studying trans- and multi-generational effects using free-living nematode Caenorhabditis elegans.
04:22
Embryo-Based Chemical Toxicity Screen: Assessing Effects on Developing Zebrafish Embryos
0 Views •
2023
In this article, zebrafish embryos are used for chemical toxicity screening. Chemical toxicity is correlated with phenotype readouts. The sample protocol shows a methodological approach of performing the chemical toxicity screening.
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
0 Views •
Cited by 76 •
2010
The intensely studied nematode worm Caenorhabditis elegans can be transgenically engineered to express the human β-amyloid peptide (Aβ). Induced expression of Aβ in C. elegans muscle leads to a rapid, reproducible paralysis phenotype that can be used to monitor treatments that modulate Aβ toxicity.
FAQs
Dose determines whether protective biological mechanisms can contain a substance's effects or become overwhelmed. Pharmacologists examine how responses change across increasing doses to identify dose-response relationships, therapeutic limits, and ranges associated with injury. This analysis helps distinguish expected pharmacological actions from harmful responses and supports selection of doses that provide benefit while reducing safety risks.
Toxicokinetics examines how exposure changes within the body over time, including the influence of absorption, distribution, metabolism, and elimination. These processes affect the concentration and duration of a compound or its metabolites at vulnerable sites. Linking toxicokinetic patterns with biological findings helps explain why toxicity may increase with prolonged exposure or differ among dosing conditions.
A substance may produce harmful responses through its metabolites as well as through the original compound. Metabolism can alter the biological activity of an exposure and may affect receptors, enzymes, cellular membranes, or organ function. Assessing both parent compounds and metabolites therefore helps pharmacologists identify the chemical forms most closely associated with tissue or physiological injury.
Cellular findings reveal how a substance disrupts membranes, enzymes, receptors, or other biological processes, while organ-level findings show how those disruptions affect integrated physiological function. Considering both levels connects a molecular or cellular mechanism with its broader consequences. This approach helps clarify the progression of injury and improves interpretation of safety findings in pharmacological research.
Evaluation begins by controlling the exposure conditions, including dose and duration, then examining dose-response patterns and toxicokinetic behavior. Researchers assess changes in tissues and physiological systems and relate those findings to the compound or its metabolites. Together, these observations help identify harmful mechanisms, establish safety limits, and determine whether a response is exposure-related.
Safety assessments reveal adverse responses that may limit a candidate drug's dose, duration of use, or suitability for further development. By comparing exposure with tissue and physiological changes, pharmacologists can identify therapeutic limits and potential organ hazards. These findings guide modifications to drug development plans and support dosing strategies intended to preserve beneficial pharmacological activity.
Dose selection requires balancing the intended pharmacological response against evidence of injury or other harmful changes. Pharmacologists use dose-response relationships, exposure duration, toxicokinetic information, and tissue or physiological findings to identify a range with acceptable safety. The resulting analysis helps define therapeutic limits and supports decisions about how much substance can be administered.
Patterns of tissue or physiological change can indicate that an adverse reaction reflects disruption of a receptor, enzyme, cellular membrane, or organ function. When these findings are considered alongside exposure and toxicokinetic data, researchers can connect the reaction to a plausible mechanism and determine how safety depends on dose, duration, or metabolite formation.